ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tambotatug pelitecan

Also written as “YL201”, “YL201 for Injection” and “Tambotatug pelitecan”.

Its studies are mostly in Small Cell Lung Carcinoma · Nasopharyngeal Carcinoma · Pancreatic Neoplasms · Esophageal Squamous Cell Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Drug pageTambotatug pelitecan: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 23, 202413 company-led studies, 13 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MediLink Therapeutics (Suzhou)its history only1212 open or runningphase 3since Sep 23, 2024Jun 16, 2022Jan 2027phase 2 · NCT07208773
Amgen11 open or runningphase 1since Mar 21, 2025Mar 21, 2025Jun 23, 2031phase 1 · NCT06898957
  • Named in hoffmann la roche’s own pipeline as RG6919 tambotatug pelitecan (MediLink), phase 1, as of Oct 22, 2026 (source).

Also a collaborator on its studies: Hoffmann-La Roche, Fosun Pharma and Akesobio.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Amgen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 21, 2025First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT06898957 · 29 enrolled · United States, Canada, China and more
  2. Jul 10, 2025Named tambotatug pelitecanINNProposed as its International Nonproprietary Name in WHO's List 133 · before, YL201

Ahead

  1. Jun 23, 2031Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT06898957

TargetBeta

“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) site-specifically conjugated to an as of yet undisclosed topoisomerase-1 inhibitor via a tumor protease-cleavable linker, with potential antineoplastic ac…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) site-specifically ”NCIt, by rule

Other programs on CD276

ProgramCompanyFurthest phaseStudies
risvutatug rezetecanHansoh Pharmaceutical Groupphase 330
ifinatamab deruxtecanMerckphase 316
Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043CSPC Pharmaceutical Groupphase 35
Anti-B7-H3 Antibody-drug Conjugate MHB088CruleMinghui Pharmaceuticalphase 34
Elfetabart DrozuntecanruleBioNTechphase 33
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruletj-biopharma-co-ltdphase 33
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01ruleradiopharm-theranostics-ltdphase 21
Autologous Anti-B7-H3 CAR T-cells BCB-276rulebrainchild-bio-incphase 21
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencorphase 12
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11
HLX316Fosun Pharmaphase 11

Studies

The one study Amgen leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06898957Small Cell Lung Carcinoma · United States, Canada, China and more1Active, not recruitingJun 23, 203129

How it is read

Names in the registry

  • “YL201”, 11 entries
  • “YL201 for Injection”, 2 entries
  • “Tambotatug pelitecan”, 1 entry
  • “YL201 and atezolizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.